Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

This study has been terminated.
Sponsor:
Collaborator:
Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy
Information provided by:
Azienda Sanitaria Ospedaliera
ClinicalTrials.gov Identifier:
NCT00320229
First received: April 18, 2006
Last updated: May 15, 2006
Last verified: January 2006
  Purpose

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications


Condition Intervention Phase
Coronary Disease
Myocardial Infarction
Drug: abciximab
Phase 4

Study Type: Interventional

Resource links provided by NLM:


Further study details as provided by Azienda Sanitaria Ospedaliera:

Estimated Enrollment: 84
Study Start Date: December 2004
Estimated Study Completion Date: July 2005
Detailed Description:

Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • presenting with unstable angina
  • presenting with acute myocardial infarction
  • eligibility for percutaneous coronary intervention

Exclusion Criteria:

  • presenting with cardiogenic shock
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00320229

Locations
Italy
Cardiologia 2 - Emodinamica - Ospedale Maggiore
Novara, Italy, 28100
Sponsors and Collaborators
Azienda Sanitaria Ospedaliera
Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy
Investigators
Principal Investigator: Mara Sansa Chief Interventional Cardiology - Ospedale Maggiore - Novara - Italy
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00320229     History of Changes
Other Study ID Numbers: ABCX-LD
Study First Received: April 18, 2006
Last Updated: May 15, 2006
Health Authority: Italy: The Italian Medicines Agency

Keywords provided by Azienda Sanitaria Ospedaliera:
angioplasty
stent
abciximab
Platelet Glycoprotein GPIIb-IIIa Complex
myocardial infarction

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Infarction
Myocardial Infarction
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Heart Diseases
Ischemia
Myocardial Ischemia
Necrosis
Pathologic Processes
Vascular Diseases
Abciximab
Anticoagulants
Hematologic Agents
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014